Proteros is a privately held early-stage services provider in structure-based drug discovery with a cutting-edge discovery engine tailored to unlock even the most technically challenging targets. Proteros’ work is built on scientific excellence and supports its clients to reach the right results and accelerate their overall research timelines. Proteros supports most of the world’s 20 largest pharma companies and more than 250 pharmaceutical and biotech partners in the US, Europe and Japan. For more information please visit www.proteros.com.
As we continue to grow, we constantly look for committed, professional and energetic people with a high sense of responsibility, who enjoy challenges.
We provide the environment for your career development and the tools you need to reach ambitious goals whilst striving for the highest standards of professional excellence. Join the Proteros team!
http://www.proteros.de/company/career/
Proteros assumes no responsibilities of whatsoever nature for the suitability of the information contained herein for the customer. All references to offers for services, including research services, crystallography services, protein supply, cryo-EM and screening services are subject to a formal offer and contract to be agreed upon by Proteros and the customer. The conditions of such contract will be set forth in the respective order process.
As we continue to grow, we constantly look for committed, professional and energetic people with a high sense of responsibility, who enjoy challenges.
We provide the environment for your career development and the tools you need to reach ambitious goals whilst striving for the highest standards of professional excellence. Join the Proteros team!
http://www.proteros.de/company/career/
Proteros assumes no responsibilities of whatsoever nature for the suitability of the information contained herein for the customer. All references to offers for services, including research services, crystallography services, protein supply, cryo-EM and screening services are subject to a formal offer and contract to be agreed upon by Proteros and the customer. The conditions of such contract will be set forth in the respective order process.
Location: Germany, Bavaria, Martinsried
Employees: 51-200
Founded date: 2000
Investors 1
| Date | Name | Website |
| 09.03.2023 | Inflexion ... | inflexion.... |
Mentions in press and media 7
| Date | Title | Description |
| 09.01.2023 | Proteros Receives Minority Investment from Inflexion | Proteros biostructures GmbH, a Munich, Germany-based contract research organization focused on early-stage drug discovery, received a minority investment from Inflexion. With the support of Inflexion as a minority investor, the company aims... |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases Signals new phase for Adrestia’s portfolio of va... |
| 25.10.2022 | Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases | Proteros selected by Adrestia for its cutting-edge structure-based drug discovery engine Proteros to support Adrestia in the discovery of first-in-class drugs for intractable genetic diseases Signals new phase for Adrestia’s portfolio of va... |
| 08.09.2020 | Proteros launches new cryo-EM facility to speed drug discovery | |
| 29.05.2014 | Rodin Therapeutics Closes $12.9M Series A Financing Round | Rodin Therapeutics, Inc., a Cambridge MA-based biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, closed a $12.9M Series A financing round. The round was led by current investors Atlas V... |
| 27.06.2013 | J&J and Atlas Venture back launch of drug developer using epigenetics to treat Alzheimer’s disease | Rodin Therapeutics has access to Proteros’ structural biology resources, including a team with a background in central nervous system drug development and company formation experience. The management team at Rodin will include Martin Jefson... |
| - | J&J and Atlas Venture back launch of drug developer using epigenetics to treat Alzheimer’s disease | Johnson & Johnson (NYSE: JNJ) kicked off the launch of its Boston innovation center with news that it is backing a new drug developer targeting Alzheimer’s disease and other neurological disorders. Early stage life science investor Atla... |